Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Reorganizes in Attempt to Focus on PGx, Metabolomics

NEW YORK, Jan. 20 (GenomeWeb News) - Clinical Data is consolidating its operations into two divisions in an attempt to focus efforts on its pharmacogenomics and metabolomics programs, the company announced today.

 

The new businesses will be called Clinical Data Molecular and Vital Diagnostics. Making up Clinical Data Molecular will be the operations acquired by the company in 2005: Genaissance (together with its Lark Technologies assets) and Icoria. The Vital Diagnostics division will consolidate the company's previously owned subsidiaries.

 

"Our emphasis will be to expand our menus of molecular services available to physicians, payors, pharmaceutical and biotechnology companies, and academic research organizations," CEO Israel Stein said in a statement.

 

The company said that the businesses comprising the Clinical Data Molecular unit generated $33 million for the 12 months ended Sept. 30. Vital Diagnostics revenues were about $53 million for that period.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.